Bowen Hanes & CO Inc Gilead Sciences, Inc. Transaction History

Bowen Hanes & CO Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$63.15 - $72.88 $277,544 - $320,307	-4,395 Reduced 49.35%	4,510 $309,000
Q4 2023 Feb 12, 2024	BUY	$73.27 - $83.09 $369,280 - $418,773	5,040 Added 130.4%	8,905 $721,000
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $421,458 - $459,819	-5,700 Reduced 59.59%	3,865 $289,000
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $1.13 Million - $1.29 Million	-14,920 Reduced 60.94%	9,565 $737,000
Q1 2023 May 11, 2023	BUY	$77.31 - $88.08 $518,750 - $591,016	6,710 Added 37.75%	24,485 $2.03 Million
Q4 2022 Feb 09, 2023	BUY	$62.32 - $89.47 $1.11 Million - $1.59 Million	17,775 New	17,775 $1.53 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $297,051 - $348,696	-4,175 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $301,059 - $356,837	4,175	4,175 $338,000

2,092

1.02B

8.73M

9.63M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $140B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bowen Hanes & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Bowen Hanes & CO Inc with notifications on news.